Curebase, a San Francisco, CA-based technology-driven clinical trial startup, raised $40m in Series B funding.
The round was led by Industry Ventures, with participation from Acrew Capital, World Innovation Lab and Positive Sum, Gaingels, GGV Capital, Bold Capital and Xfund. The round also included a strategic investment by global biopharmaceutical company Gilead Sciences.
The company, which has raised a total of $59m, intends to use the funds to continue development of its solutions.
Founded in 2017 by CEO Tom Lemberg, Curebase provides decentralized clinical trials (DCTs) and patient-centric clinical trial software. The company’s virtual and hybrid research sites offer patients the opportunity to participate in clinical studies, regardless of their location via community provider facilities and home-based care. The platform empowers sponsors and physicians from practices of all sizes to conduct clinical research, including private practices, independent clinics, and large academic research sites.
The company has now run over 50 studies to date, with 300-400% growth year over year.
FinSMEs
05/05/2022